Clinical Trials Using Entinostat

Clinical trials are research studies that involve people. The clinical trials on this list are studying Entinostat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-17 of 17
  • Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients with Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

    This phase Ib trial studies the side effects and best dose of entinostat when given together with pembrolizumab in treating patients with myelodysplastic syndrome after deoxyribonucleic acid (DNA) methyltransferase inhibitor (DNMTi) therapy failure. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving entinostat together with pembrolizumab may work better in treating patients with myelodysplastic syndrome after DNMTi therapy failure.
    Location: 16 locations

  • A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

    This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following treatment with a cyclin-dependent kinase (CDK) 4 / 6 inhibitor in the first- or second-line setting, such as palbociclib, ribociclib, or abemaciclib. The study will be performed in two stages. During Stage 1, participants will be randomized to fulvestrant (control) or an atezolizumab-containing doublet or triplet combination. Those who experience disease progression, loss of clinical benefit, or unacceptable toxicity may be eligible to receive a new triplet combination treatment in Stage 2 until loss of clinical benefit or unacceptable toxicity. New treatment arms may be added and / or existing treatment arms may be closed during the course of the study on the basis of ongoing clinical efficacy and safety as well as the current treatments available.
    Location: 7 locations

  • Pembrolizumab and Entinostat in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

    This phase II trial studies how well pembrolizumab and entinostat work in treating patients with classical Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and entinostat may work better in treating patients with classical Hodgkin lymphoma.
    Location: 7 locations

  • High Dose Aldesleukin with or without Entinostat in Treating Patients with Metastatic or Unresectable Renal Cell Cancer

    This phase II trial studies how well high dose aldesleukin with or without entinostat work in treating patients with renal cell cancer that has spread to other areas of the body (metastatic) or cannot be removed by surgery (unresectable). Interleukins are proteins made by white blood cells and other cells in the body that may help regulate immune response. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if high dose aldesleukin with or without entinostat may work better in treating patients with renal cell cancer.
    Location: 6 locations

  • Entinostat, Nivolumab, and Ipilimumab in Treating Patients with Metastatic Renal Cell Cancer

    This phase II trial studies the side effects and best dose of entinostat when given together with nivolumab and ipilimumab in treating patients with renal cell cancer that has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving entinostat, nivolumab, and ipilimumab may work better in treating patients with renal cell cancer.
    Location: 3 locations

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: 3 locations

  • Entinostat and Azacitidine in Treating Older Patients with Acute Myeloid Leukemia

    This randomized phase II trial studies how well giving two different schedules of entinostat together with azacitidine works in treating older patients with acute myeloid leukemia. Entinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which schedule of entinostat is more effective in treating acute myeloid leukemia.
    Location: 2 locations

  • Pembrolizumab with or without Entinostat in Treating Patients with Bladder Urothelial Cancer

    This phase II trial studies the changes in immune response to pembrolizumab with or without entinostat in patients with bladder urothelial cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to find out the effect of pembrolizumab and entinostat on tumor and immune cells. This may help the researchers to understand how pembrolizumab alone or in combination of with entinostat can help the immune system find and fightbladder urothelial cancer.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Entinostat and Pembrolizumab in Treating Patients with Stage III-IV Melanoma

    This phase II trial studies how well entinostat and pembrolizumab work in treating patients with stage III-IV melanoma. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving entinostat and pembrolizumab may work better in treating patients with stage III-IV melanoma.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Entinostat and Capecitabine in Treating Patients with HER2 Negative Stage I-IV Invasive Breast Cancer

    This phase I / II trial studies side effects and best dose of entinostat and capecitabine in treating patients with HER2 negative stage I-IV invasive breast cancer. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving entinostat and capecitabine may work better in treating patients with breast cancer.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Entinostat and Nivolumab in Treating Patients with Unresectable or Metastatic Cholangiocarcinoma or Pancreatic Adenocarcinoma

    This phase II trial studies how well entinostat and nivolumab work in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma that cannot be removed by surgery or has spread to other places in the body. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving entinostat with nivolumab may work better in treating patients with cholangiocarcinoma or pancreatic adenocarcinoma compared to standard treatments.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Regorafenib, Hydroxychloroquine, and Entinostat in Treating Patients with Metastatic Colorectal Cancer

    This phase I / II trial studies the side effects and best dose of hydroxychloroquine and entinostat when given together with regorafenib, and to see how well they work in treating patients with colorectal cancer that has spread to other places in the body. Hydroxychloroquine may help decrease resistance to chemotherapy, entinostat may help to disrupt the signaling of cancer cells, and regorafenib may help to decrease the blood supply of a tumor. Giving hydroxychloroquine, entinostat, and regorafenib together may work better in treating patients with colorectal cancer.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Entinostat in Treating Patients with Relapsed or Refractory Stage IV Abdominal Neuroendocrine Tumor That Cannot Be Removed by Surgery

    This phase II trial studies how well entinostat works in treating patients with stage IV abdominal neuroendocrine tumor that has come back or does not respond to treatment or cannot be removed by surgery. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

    Background: Breast cancer is the second most common cause of U.S. cancer deaths in women. Immunotherapy drugs use a person s immune system to fight cancer. Researchers want to see if a new combination of immunotherapy drugs can help treat breast cancer that has gone to places in the body outside of the breast (metastasized). Objective: To learn if a new combination of immunotherapy drugs can shrink tumors in people with metastatic breast cancer. Eligibility: Adults 18 and older who have been diagnosed with metastatic breast cancer, such as Triple Negative Breast Cancer (TNBC) or ER- / PR- / HER2+ Breast Cancer (HER2+BC) Design: Participants will be screened with: medical history physical exam disease confirmation (or tumor biopsy) tumor scans (computed tomography, magnetic resonance imaging, and / or bone scan) blood and urine tests electrocardiogram (measures the heart s electrical activity) echocardiogram (creates images of the heart). Participants will be assigned to 1 of 3 groups. The drugs they get will be based on the group they are in. Drugs are given in cycles. Each cycle = 3 weeks. Participants will be seen in clinic every 3 weeks, prior to the start of a new cycle. At each visit, participants will have an clinical exam, have blood drawn and will be asked about any side effects. They will repeat the screening tests during the study. New scans, like a CT scan, will be done every 6 weeks to see if the treatment is working. All participants will get BN-Brachyury. It is 2 different vaccines - a prime and a boost. First the priming vaccines, called MVA-BN-Brachyury help to jump start the immune system. Next the boosting vaccines, called FPV-Brachyury help to keep the immune system going. They are injected under the skin during different cycles. All participants will get M7824 (also known as Bintrafusp alfa ), which is an immunotherapy drug. Some participants will get a commonly used drug is HER2+ breast cancer called adotrastuzumab emtansine (also known as T-DM1DM1 or kadcyla). For both, a needle is inserted into a vein to give the drugs slowly. Some participants will take Entinostat weekly by mouth. It is in tablet form. Participants will keep a pill diary. Participants will continue on their assigned treatment until their cancer grows, they develop side effects or want to stop treatment. About 28 days after treatment ends, participants will have a follow-up visit or a telephone call. Then they will be contacted every 3 months for 1 year, then every 6 months for 1 year. They may have more tumor scans or continue treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Entinostat and the FOLFOX Chemotherapy Regimen in Treating Patients with Metastatic Pancreatic Cancer

    This phase Ib trial studies the best dose of entinostat when given together with the standard of care FOLFOX chemotherapy regimen in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in the FOLFOX chemotherapy regimen, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving the standard FOLFOX regimen together with entinostat may work better in treating patients with pancreatic cancer compared to the FOLFOX regimen alone.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

    This phase I / II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Tumor samples from patients will be tested for a specific change in their genetic materials (DNA) called homologous recombination deficiency (HRD). Patients who lack this genetic change will be eligible to participate in this study. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Entinostat in Treating Patients with Newly Diagnosed, Stage I-IIIC, Invasive Hormone Receptor Positive, or Triple Negative Breast Cancer

    This clinical trial studies how entinostat works in treating patients with newly diagnosed, stage I-IIIC invasive triple negative breast cancer. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina